Please login to the form below

Not currently logged in
Email:
Password:

Ruconest

This page shows the latest Ruconest news and features for those working in and with pharma, biotech and healthcare.

EMA starts rapid review of Shire’s HAE antibody

EMA starts rapid review of Shire’s HAE antibody

Other approved treatments for HAE include CSL Behring’s Berinert and Pharming’s Ruconest.

Latest news

  • Opdivo backed for two new uses by CHMP Opdivo backed for two new uses by CHMP

    The CHMP also recommended extensions of indications for Boehringer Ingelheim's Giotrif (afatinib), Abbvie's Humira (adalimumab), Pharming's Ruconest (conestat alfa), Takeda's TachoSil (human thrombin/human fibrinogen) and

  • Valeant and Shire said to be evaluating potential Salix bids Valeant and Shire said to be evaluating potential Salix bids

    Nevertheless, in the latter half of last year Salix introduced three new products - Ruconest for hereditary angioedema, Relistor (methylnaltrexone bromide) subcutaneous injection for chronic non-cancer pain and Uceris (budesonide) rectal

  • FDA approves drug for rare swelling diseases FDA approves drug for rare swelling diseases

    FDA approves drug for rare swelling diseases. Salix and Pharming’ s Ruconest is made from the milk of genetically-modified rabbits. ... Ruconest is developed in partnership by Salix Pharmaceutical and Pharming and is intended as a protein replacement

  • Trial delay prompts Pharming to look at "strategic alternatives"

    Trial delay prompts Pharming to look at "strategic alternatives". Dutch biotech awaits key milestone payment relating to its lead drug Ruconest. ... Another $5m is payable on filing of a Biologics License Application (BLA) for Ruconest, provided the US

  • Meeting with resistance

    Dry eyes. Japan. Conestat alfa. Ruconest (Swedish Orphan Biovitrum). Hereditary angioedema.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    Finally it was interesting to see that Pharming has recovered from Valeant the North American rights to its product Ruconest. ... 151. Valeant (US). Pharming (NL). Asset acquisition North America. Ruconest (recombinant human C1 esterase inhibitor) for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics